Open AccessPlatelet aggregation activity and beta-adrenoblocker therapy in patients with dilated cardiomyopathy
Author(s) -
П. Н. Исаханова,
Yu. N. Ziyaev,
Х. А. Маматкулов,
М. Х. Назарова,
Sh. I. Makhamatova
Publication year - 2012
Publication title -
kardiovaskulârnaâ terapiâ i profilaktika
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.158
H-Index - 16
eISSN - 2619-0125
pISSN - 1728-8800
DOI - 10.15829/1728-8800-2012-1-59-62
Subject(s) - bisoprolol , atenolol , medicine , cardiology , dilated cardiomyopathy , beta (programming language) , platelet aggregation , cardiomyopathy , platelet , ischemic cardiomyopathy , heart failure , blood pressure , ejection fraction , computer science , programming language
Aim. To investigate the specifics of ischemic and idiopathic dilated cardiomyopathy (DCMP), platelet aggregation activity, and the reaction of the latter to the beta-adrenoblocker (β-AB) therapy with atenolol or bisoprolol. Results. In DCMP patients, a significant increase in velocity and maximal amplitude of ADP-induced platelet aggregation, as well as a significant reduction in the time to the maximal aggregation amplitude, was observed. In both therapy groups, all parameters of platelet aggregation activity were significantly higher in ischemic vs. idiopathic DCMP patients. Long-term bisoprolol therapy provided a more manifested antiaggregant effect of the basis treatment, compared to atenolol therapy. Conclusion. DCMP patients, especially ones with ischemic DCMP, demonstrated an increase in platelet aggregation activity. Long-term bisoprolol therapy facilitated a more pronounced anti-aggregant effect of the basis treatment, compared to atenolol treatment.